Curaleaf Holdings, Inc. is a listed company. Filings by its managers are published through SEDI. The last twelve months, up to 18 October 2026, brought 146 filings signed by 15 insiders.
Only sales appear on the open market, 3 sales in all totalling €713k, filed by 3 insiders. The largest single trade was a sale of €470k by Pinto, Rahul, published on 26 June 2026, equal to 0.017% of the market capitalisation.
Between a trade and the moment it shows up on SEDI, the median delay is 20 days. Until a filing is published, the market cannot know about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 146 filings in twelve months, the company is more active than the median of 11 filings across the 2,121 companies we follow on the same exchange. Since 2026, the database holds no purchases and 3 sales by insiders of the company.
Source: insider filings from SEDI. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 146 declarations
Curaleaf Holdings, Inc. is a Canadian company focused on the production and distribution of cannabis-based products. It is listed on the Toronto Stock Exchange under the symbol XTSE.
Insider filings
Over the last 90 days, 96 filings published between 21 July and 9 October 2026: 2 sales for €242k. 52 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). The company also filed 42 transactions in its own shares (buybacks or cancellations) for €845k; these are not insider purchases. Largest amounts: Johansson, Karl (4 - Director of Issuer), sales of €233k; Sciarrone, Robert (5 - Senior Officer of Issuer), sales of €8,927.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 16 October 2026 (UTC)
Curaleaf’s chief legal officer bought on July 17 as cannabis policy momentum, listed options, and peer activity frame th...
Curaleaf is consolidating near recent levels as Peter Laurence Clateman bought shares again. Here is what the filing mea...